Vered Daitch
Impact in
- Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
-
- Antibiotic Use and Resistance
Papers in
-
- Antibiotic Resistance in Bacteria 11
-
- Antibiotic Use and Resistance 5
- Co-authors
- Leonard Leibovici (15 shared papers)Mical Paul (8 shared papers)Dafna Yahav (9 shared papers)Oren Zusman (4 shared papers)Adi Turjeman (3 shared papers)Noam Tau (2 shared papers)Irit Ayalon‐Dangur (2 shared papers)Laura Farbman (5 shared papers)
In The Last Decade
Vered Daitch
30 papers receiving 1.2k citations
Vered Daitch's Hit Papers
Peers
Comparison fields: 5 of 71
- Molecular Medicine 735
- Applied Microbiology and Biotechnology 69
- Pharmacology 135
- Critical Care and Intensive Care Medicine 37
- Clinical Biochemistry 35
Countries citing papers authored by Vered Daitch
This map shows the geographic impact of Vered Daitch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vered Daitch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vered Daitch more than expected).
Fields of papers citing papers by Vered Daitch
This network shows the impact of papers produced by Vered Daitch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vered Daitch. The network helps show where Vered Daitch may publish in the future.
Co-authors
The 25 scholars most cited alongside Vered Daitch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial Hit paper breakdown → | 2018 | 513 |
| 2 | 2018 | 102 | |
| 3 | 2022 | 77 | |
| 4 | 2020 | 64 | |
| 5 | 2022 | 54 | |
| 6 | 2016 | 50 | |
| 7 | 2022 | 44 | |
| 8 | 2018 | 37 | |
| 9 | 2014 | 34 | |
| 10 | 2020 | 32 | |
| 11 | 2018 | 28 | |
| 12 | 2023 | 24 | |
| 13 | 2015 | 17 | |
| 14 | 2019 | 17 | |
| 15 | 2022 | 16 | |
| 16 | 2021 | 14 | |
| 17 | 2021 | 9 | |
| 18 | 2014 | 7 | |
| 19 | 2018 | 7 | |
| 20 | 2014 | 5 |
About Vered Daitch
Vered Daitch is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology, Neurology, Pharmacology and Statistics, Probability and Uncertainty, having authored 32 papers that have together received 1.2k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (11 papers), Antibiotic Use and Resistance (5 papers), Long-Term Effects of COVID-19 (4 papers), Sepsis Diagnosis and Treatment (3 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers), Meta-analysis and systematic reviews (2 papers), Antimicrobial Resistance in Staphylococcus (1 paper) and Hospital Admissions and Outcomes (1 paper). The work is most often cited by research in Molecular Medicine (735 citations), Applied Microbiology and Biotechnology (69 citations), Pharmacology (135 citations), Critical Care and Intensive Care Medicine (37 citations) and Clinical Biochemistry (35 citations). Vered Daitch has collaborated with scholars based in Israel, Italy and Greece. Frequent co-authors include Leonard Leibovici, Mical Paul, Dafna Yahav, Oren Zusman, Adi Turjeman, Noam Tau, Irit Ayalon‐Dangur, Laura Farbman, Adi Lador and Sergey Altunin. Their work appears in journals such as Clinical Infectious Diseases, Clinical Microbiology and Infection, European Journal of Clinical Microbiology & Infectious Diseases, Scientific Reports and Annals of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.